Inflammatory Bowel Disease Associates with Proinflammatory Potential of the Immunoglobulin G Glycome
Year: 2015
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Glycobiology is an underexplored research area in inflammatory bowel disease (IBD), and glycans are relevant to many etiological mechanisms described in IBD. Alterations in N-glycans attached to the immunoglobulin G (IgG) Fc fragment can affect molecular structure and immunological function. Recent genome-wide association studies reveal pleiotropy between IBD and IgG glycosylation. This study aims to explore IgG glycan changes in ulcerative colitis (UC) and Crohn's disease (CD). METHODS: IgG glycome composition in patients with UC (n = 507), CD (n = 287), and controls (n = 320) was analyzed by ultra performance liquid chromatography. RESULTS: Statistically significant differences in IgG glycome composition between patients with UC or CD, compared with controls, were observed. Both UC and CD were associated with significantly decreased IgG galactosylation (digalactosylation, UC: odds ratio [OR] = 0.71; 95% confidence interval [CI], 0.5-0.9; P = 0.01; CD: OR = 0.41; CI, 0.3-0.6; P = 1.4 × 10) and significant decrease in the proportion of sialylated structures in CD (OR = 0.46, CI, 0.3-0.6, P = 8.4 × 10). Logistic regression models incorporating measured IgG glycan traits were able to distinguish UC and CD from controls (UC: P = 2.13 × 10 and CD: P = 2.20 × 10), with receiver-operator characteristic curves demonstrating better performance of the CD model (area under curve [AUC] = 0.77) over the UC model (AUC = 0.72) (P = 0.026). The ratio of the presence to absence of bisecting GlcNAc in monogalactosylated structures was increased in patients with UC undergoing colectomy compared with no colectomy (FDR-adjusted, P = 0.05). CONCLUSIONS: The observed differences indicate significantly increased inflammatory potential of IgG in IBD. Changes in IgG glycosylation may contribute to IBD pathogenesis and could alter monoclonal antibody therapeutic efficacy. IgG glycan profiles have translational potential as IBD biomarkers.
Source: Inflammatory Bowel Diseases
Authors: Irena Trbojević Akmačić, Nicholas T. Ventham, Evropi Theodoratou, Frano Vučković, Nicholas A. Kennedy, Jasminka Krištić, Elaine R. Nimmo, Rahul Kalla, Hazel Drummond, Jerko Štambuk, Malcolm G. Dunlop, Mislav Novokmet, Yurii Aulchenko, Olga Gornik, Harry Campbell, Maja Pučić Baković, Jack Satsangi, Gordan Lauc
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: inflammatory bowel disease, IgG glycosylation
Open Access status: hybrid
Estimated APC paid: $3,862
Funders: Sveučilište u Zagrebu, Wellcome Trust, Cedars-Sinai Medical Center, Cancer Research UK, European Commission, University of Edinburgh, Universiteit Leiden, Vrije Universiteit Amsterdam, Universiteit Maastricht, Università degli Studi di Padova, Maastricht Universitair Medisch Centrum, Leids Universitair Medisch Centrum, Russian Science Foundation, Inflammatory Bowel and Immunobiology Research Institute
Awards: Diagnostic and prognostic biomarkers for inflammatory bowel disease
IBD-BIOM, An investigation into the epigenetic alterations in the T helper 17 pathway in the pathogenesis of Crohn's disease., G3533274893, Integrating research in molecular life sciences at the University of Zagreb, Methods for high-throughput glycoproteomic analysis, Methods for Integrated analysis of Multiple Omics datasets, Methods for high-throughput (HTP) analysis of protein glycosylation, G7964317829
OpenAlex ID: W2058178814
